Navigation Links
Pharmaxis Investor Conference Call

SYDNEY, Australia, April 6 /PRNewswire-Asia/ -- Pharmaxis Ltd (AXS: PXS; Nasdaq: PXSL) will release its March 2009 Quarterly Report to Shareholders on the afternoon of Wednesday 8th April 2009. Dr Alan Robertson will host an investor teleconference the following morning to review the quarter and answer investor questions.

The teleconference will be on Thursday 9th April at 8.00am (Sydney), (Wednesday 8th April at 6.00pm U.S. East Coast, 3.00pm U.S. West Coast).

    Telephone access (toll free) details are below:
    -- Australia: 1800 131 617
    -- USA/Canada:  866 746 2596
    -- UK: 0800 376 8339
    -- NZ: 0800 446 958
    -- Switzerland: 0800 001 230
    -- Online (global access):

A recording of the conference will be available on the Pharmaxis website home page approximately 3 hours after the call.


     Pharmaxis Investor Relations
     Tel:     +61-2-9454-7200
     Fax:     +61-2-9451 3622,

SOURCE Pharmaxis Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Pharmaxis Appoints French Distributor for Aridol(TM)
2. Pharmaxis Builds Senior Management Team
3. Pharmaxis Investor Conference Call
4. Pharmaxis Aridol Approved for Sale in Switzerland
5. Pharmaxis Investor Conference Call
6. Pharmaxis Research Programs Highlighted at European Respiratory Society Congress
7. New Pharmaxis Board Appointment
8. Pharmaxis Aridol Authorised for Sale in Germany
9. Pharmaxis First Steps into China
10. Pharmaxis to Apply to Market Bronchitol in Australia
11. Pharmaxis Investor Conference Call
Post Your Comments:
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, ... second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical ... eBook by providing practical tips, tools, and strategies for clinical researchers. , “The ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. ... test has received AOAC Research Institute approval 061601. , “This is another AOAC-RI ... stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
Breaking Biology Technology:
(Date:6/16/2016)... June 16, 2016 The ... expected to reach USD 1.83 billion by 2024, ... Research, Inc. Technological proliferation and increasing demand in ... expected to drive the market growth. ... The development of advanced multimodal techniques for ...
(Date:6/3/2016)... Das DOTM (Department ... hat ein 44 Millionen $-Projekt ... einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an Decatur ... Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale Anbieter ... aber Decatur wurde als konformste und innovativste ...
(Date:5/24/2016)... May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology ... LCD display is the latest premium product recently added to the range of products ... ... ... 3d Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):